Beatriz Domínguez-Gil

Beatriz Domínguez-Gil occupies a connective role in the volume: she is named among its co-editors, associated with Madrid, and identified professionally with the Organización Nacional de Trasplantes. Her most substantial contribution is the chapter on renal transplantation from donors with positive hepatitis C virus serology, where she appears as the lead author alongside Nuria Esforzado, Amado Andrés, Josep M. Campistol, and Jose M. Morales. Her work places her at the intersection of transplant medicine, infectious-disease risk, waiting-list policy, and the practical scarcity of donated kidneys.

Identity and Professional Setting

Beatriz Domínguez-Gil is presented in the editorial apparatus as a co-editor of the volume, with Madrid attached to her name. The same Madrid association appears in the contents for the chapter on renal transplantation from donors with positive hepatitis C virus serology, establishing continuity between her editorial responsibility and her subject-matter expertise. The chapter’s institutional affiliations identify her with the Organización Nacional de Trasplantes in Madrid, Spain, while the other authors are linked to nephrology departments in Barcelona and Madrid. At the chapter’s close, she is listed as MD, PhD, with the Organización Nacional de Trasplantes and a Madrid address, giving her role a concrete institutional and professional location.

Her contribution is therefore not that of a patient or a fictional protagonist but of a medical author and transplant-policy participant. The evidence associates her with the production and organization of specialist knowledge: she helps assemble clinical experience, registry findings, international recommendations, and proposals for changing organ-allocation practice. Her importance in the book lies in making a contested transplant practice legible as both a medical decision and a problem of public organization.

The Chapter and Its Central Problem

Domínguez-Gil’s chapter addresses the continued controversy over transplanting kidneys from hepatitis C virus-seropositive donors into hepatitis C virus-positive recipients. It begins from a global imbalance: organ transplantation benefits about 100,000 patients worldwide each year, yet the supply of organs remains far below demand. At the end of 2009, approximately 63,000 people were on an organ waiting list in the European Union while only 28,000 transplant procedures were performed; in the United States, almost 111,000 people were registered in May 2011, against roughly 28,000 procedures annually. Within that shortage, rejecting every kidney from a seropositive donor can mean discarding an organ that might otherwise be used.

The chapter explains why the issue is difficult. Hepatitis C virus can be transmitted through organ transplantation, so seropositive donors are classified as non-standard-risk donors. Many centers never accept their kidneys, and some countries impose technical or legal restrictions. At the same time, the incidence and prevalence of active hepatitis C virus infection among patients with end-stage renal disease have declined because of preventive measures and expanded antiviral treatment. The result is a paradox: the very success of treatment and prevention reduces the number of suitable hepatitis C virus-positive recipients, making seropositive-donor kidneys increasingly likely to become surplus organs even while the general shortage remains acute.

Evidence and Clinical Judgment

The evidence presented under Domínguez-Gil’s authorship distinguishes center-based experience from registry-based warnings rather than pretending that the controversy has a single uncomplicated answer. In March 1990, two Spanish kidney-transplant units began a pilot program using kidneys from seropositive donors in hepatitis C virus-positive recipients. Early results showed similar graft and patient survival regardless of donor serology, and comparable proportions of recipients developed biochemical evidence consistent with chronic liver disease. Yet retrospective polymerase chain reaction testing revealed an important limitation: five recipients who had been RNA-negative received kidneys from donors with positive viral RNA; four subsequently became RNA-positive, and two developed chronic liver disease.

That discovery changed the Spanish policy in March 1993. The use of these kidneys was restricted to waiting-list patients who already had positive hepatitis C virus RNA before transplantation. Later single-center reports using the same basic approach produced similar short-term results, and several found that hepatitis C virus-positive recipients who accepted kidneys from seropositive donors spent significantly less time on the waiting list. The practice thus became a form of risk matching: it did not eliminate viral danger, but it sought to avoid transferring infection to a recipient without demonstrable active infection while offering a faster route to transplantation for someone already living with the virus.

Registry evidence complicated the favorable picture. Analyses from the United States Renal Data System reported lower patient survival after transplantation from seropositive rather than seronegative donors, regardless of the recipient’s hepatitis C virus serology, with the difference becoming apparent about two years after transplantation. A higher incidence of posttransplant diabetes mellitus was proposed as an intermediate complication that might help explain the later excess mortality. These findings led to a recommendation for caution and for complete information to be given to potential recipients before transplantation. Domínguez-Gil’s presentation preserves this tension between encouraging local series and contradictory registry results, making uncertainty itself part of the clinical evidence.

Policy, Consent, and Organ Use

The chapter’s recommendations are conditional rather than absolute. Long-term experience suggests that transplantation from seropositive donors into recipients with active hepatitis C virus infection can be safe, particularly when recipients are positive for hepatitis C virus RNA before transplantation. The authors further propose, where circumstances permit, matching donor and recipient according to viral genotype, since avoiding superinfection may depend on whether the strains involved are compatible or different. They acknowledge, however, that genotype matching is constrained by the limited time available when organs are offered.

Domínguez-Gil also sets this choice against the limits of pretransplant antiviral treatment. Interferon-based therapy can produce adverse events, requires a prolonged course, excludes patients from the waiting list during treatment, fails in a substantial minority, may be refused or discontinued, and is not universally affordable. A patient with positive viral RNA may therefore be untreated not because treatment is clinically irrelevant, but because toxicity, access, nonresponse, or personal choice makes eradication unattainable. For such patients, the chapter argues that transplantation may still offer a more favorable course than remaining on dialysis, and an organ from a seropositive donor may shorten the waiting period.

That argument makes informed acceptance essential. The potential recipient must understand the possibility of viral transmission, superinfection, posttransplant complications, and uncertain long-term outcomes, while also understanding the concrete danger of continued dialysis and prolonged waiting. The chapter does not reduce consent to a formal signature; it treats the decision as a negotiation between risks that cannot be removed and benefits that may be lost if every seropositive kidney is rejected.

Change, Consequences, and Significance

The concluding position associated with Domínguez-Gil is that kidneys from hepatitis C virus-seropositive donors should not automatically be wasted. Center-based evidence indicates favorable graft survival, patient survival, and hepatitis C virus-related liver outcomes in hepatitis C virus-positive recipients. Safety can be improved by limiting transplantation to recipients with positive viral RNA and, ideally, by matching donor and recipient genotypes. The policy is therefore framed as a controlled expansion of the donor pool rather than a return to indiscriminate transplantation.

The chapter also identifies an institutional failure behind the apparent surplus. Donated seropositive kidneys were reported to be 2.60 times more likely to be discarded than seronegative kidneys, while acceptance practices varied widely between centers. The proposed remedy is organizational: centers should develop mechanisms for transferring these organs when they are not used locally, consider preemptive transplantation for hepatitis C virus RNA-positive recipients who will not receive interferon therapy, and pursue international cooperation. Domínguez-Gil’s contribution thus ends by shifting attention from the infected organ alone to the system that decides whether an organ is usable.

Her narrative role in the volume is consequently both evidentiary and reformist. She gathers the history of Spanish practice, acknowledges adverse findings, clarifies the boundaries of acceptable matching, and argues that persistent hesitation has a human and logistical cost during dramatic organ shortage. The decisive significance of her work is its refusal of a simple opposition between safety and access: with screening, viral-status assessment, disclosure, and better allocation structures, a previously rejected kidney can become a carefully managed opportunity for transplantation.